
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Ioxaglic acid
Introduction
{{Drugbox | IUPAC_name = 3-[(2-hydroxyethyl)carbamoyl]-2,4,6-triiodo-5-(2-{[2,4,6-triiodo-3-(methylcarbamoyl)-5-(N-methylacetamido)phenyl]formamido}acetamido)benzoic acid | image = Ioxaglic acid wiki str.png
| tradename =
| Drugs.com = International Drug Names
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration =
| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =
| CAS_number =
| ATC_prefix = V08
| ATC_suffix = AB03
| PubChem = 3742
| DrugBank =
| UNII_Ref = Â
| UNII = Z40X7EI2AF
| KEGG = D01761
| ChEMBL = 1201291
| ChemSpiderID = 3611
| chemical_formula = | C=24 | H=21 | I=6 | N=5 | O=8 | molecular_weight = 1268.87906 g/mol | smiles = CC(=O)N(C)C1=C(C(=C(C(=C1I)C(=O)NCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)C(=O)NCCO)I)I)C(=O)NC)I | InChI = 1/C24H21I6N5O8/c1-7(37)35(3)20-17(29)10(21(39)31-2)13(25)11(18(20)30)23(41)33-6-8(38)34-19-15(27)9(22(40)32-4-5-36)14(26)12(16(19)28)24(42)43/h36H,4-6H2,1-3H3,(H,31,39)(H,32,40)(H,33,41)(H,34,38)(H,42,43) | InChIKey = TYYBFXNZMFNZJT-UHFFFAOYAE | StdInChI = 1S/C24H21I6N5O8/c1-7(37)35(3)20-17(29)10(21(39)31-2)13(25)11(18(20)30)23(41)33-6-8(38)34-19-15(27)9(22(40)32-4-5-36)14(26)12(16(19)28)24(42)43/h36H,4-6H2,1-3H3,(H,31,39)(H,32,40)(H,33,41)(H,34,38)(H,42,43) | StdInChIKey = TYYBFXNZMFNZJT-UHFFFAOYSA-N
}}
Overview
Overview
Ioxaglic acid (trade name Hexabrix) is an iodine containing molecule used as a low-osmolality contrast medium.[1]
References
References
- ↑ PMID 6999377 (PMID 6999377)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
